Supernus Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
549300GRM36VBKISYJ58 - ISIN
US8684591089 (SUPN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€81.60 99.0% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Read full profile
Fundamentals
- Net revenue
€567.32M - Gross margin
79.5% - EBIT
€53.85M - EBIT margin
9.5% - Net income
€55.01M - Net margin
9.7%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
|
|
|
|
| Khattar Jack A. | President, CEO |
|
|
|
|
| NEWHALL CHARLES W III | N/A |
|
|
|
|
| Khattar Jack A. | President, CEO |
|
|
|
|
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | April 7, 2025 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 8, 2024 (Q1 2024)